Duolingo Shares Decline 22% Following Profitability Pivot Announcement

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Duolingo stock fell 22% after announcing a shift toward user acquisition and AI development, sacrificing near-term profits. User growth decelerated to slowest pace in four years.

Duolingo Shares Decline 22% Following Profitability Pivot Announcement

Duolingo's stock fell 22 percent on February 27, 2026, following the company's announcement to shift strategic priorities toward user acquisition and artificial intelligence development at the expense of near-term profitability. The language learning platform disclosed guidance indicating a slowdown in earnings expansion and compression of operating margins, signaling a deliberate trade-off between growth investments and financial performance in the coming quarters.

The company projected first-quarter adjusted EBITDA of $73.6 million, falling short of analyst consensus expectations of $84 million. This shortfall reflected the financial impact of Duolingo's reoriented investment strategy. Meanwhile, daily active user growth decelerated to 30 percent year-over-year, marking the platform's slowest expansion rate in four years and raising questions about user acquisition momentum despite the company's renewed focus on growth.

Duolingo outlined ambitious expansion targets, targeting a doubling of its daily active user base to 100 million by 2028. The company's strategic recalibration indicates management's willingness to accept near-term margin pressure in pursuit of expanded market share and technological advancement, a shift that the market initially received with caution given the deceleration in user growth metrics.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO